Ethical protocol for blood sampling from healthy adult volunteers for research on the immune answer towards biotherapeutic drugs in development
| ISRCTN | ISRCTN46694886 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN46694886 |
| Secondary identifying numbers | N/A |
- Submission date
- 01/06/2015
- Registration date
- 01/07/2015
- Last edited
- 18/11/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Plain English summary of protocol
Background and study aims
Nanobodies® are a recently discovered class of proteins, which show great therapeutic and diagnostic potential in diseases such as cancer. They have many advantages over classical biotherapeutics (engineered biological products), but since Nanobodies originate from camelid animals (e.g. camels and alpacas) there is a risk of unwanted side effects, particularly immune system responses, when used in humans. These responses may drastically limit how effective the therapy is, and in certain cases can even be very harmful for the patient. The aim of this study is to investigate the cause of unwanted immune system reactions to Nanobodies. Specifically, this study will examine the non-human (camelid) aspects of the Nanobodies protein, production side-products and formulation to analyse the main steps responsible for inducing an immune response in humans. This will be done by taking blood samples from healthy volunteers, which will then be analysed in the laboratory to isolate specific, highly sensitive cells that are known to be critical in initiating an immune system response.
Who can participate?
Healthy adults aged 18-65.
What does the study involve?
All participants are asked to give a blood sample.
What are the possible benefits and risks of participating?
The results of this study will be used to generate safer and more efficient Nanobodies, resulting in healthier patients and reduced health costs.
Where is the study run from?
1. Free University of Brussels (Vrije Universiteit Brussel) (Belgium)
2. University Hospital Brussels (Universitair Ziekenhuis Brussel) (Belgium)
When is the study starting and how long is it expected to run for?
July 2015 to June 2018
Who is funding the study?
Free University of Brussels (Vrije Universiteit Brussel) (Belgium)
Who is the main contact?
Dr C Ackaert
Contact information
Scientific
VUB, Building E, 8th Floor
Pleinlaan 2
Elsene
1050
Belgium
 ORCID ID |
0000-0001-9145-2931 |
|---|
Study information
| Study design | Single-centre trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | GP practice |
| Study type | Other |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet. |
| Scientific title | Ethical protocol for blood sampling from healthy adult volunteers for research on risk mitigation of immunogenicity of Nanobodies® |
| Study objectives | Rationale of the study: to determine immunogenic regions in the sequence of Nanobodies to be able to change these regions to generate more safe and less immunogenic Nanobodies. |
| Ethics approval(s) | Ethics Committee of the University Hospital Brussels (UZ Brussel), Belgium - submission planned for 05/06/2015. |
| Health condition(s) or problem(s) studied | Blood sampling from healthy, adult volunteers for isolation of peripheral blood mononuclear cells (PBMCs) for in vitro analysis of the human immune response towards Nanobodies. |
| Intervention | Blood sampling (up to 450 ml). Nothing is administered. |
| Intervention type | Procedure/Surgery |
| Primary outcome measure | T cell proliferation and differentiation in vitro as surrogate marker for the in vivo development of anti-drug antibody formation, measured 1-2 weeks after blood sampling. |
| Secondary outcome measures | Immunogenic regions of the Nanobodies are identified and mutated, and the resulting new Nanobodies are tested once again for immunogenicity. Measurements are carried out 2.5 years after blood sampling. |
| Overall study start date | 01/07/2015 |
| Completion date | 30/06/2018 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 65 Years |
| Sex | Both |
| Target number of participants | 300 |
| Key inclusion criteria | 1. Good general health 2. Aged 18-65 |
| Key exclusion criteria | 1. Pregnant (in case of doubt, a test will be taken) or envisages a pregnancy in the near future 2. History of significant inconvenience with blood sampling 3. High risk for HIV, HBV or HCV 4. Has received blood or blood products in the last 6 months 5. Has received any therapeutic treatment that influences the immune system 6. Presence of acute or chronic infection or disease 7. Currently taking drugs, except for contraceptives 8. Associated with the current study |
| Date of first enrolment | 01/07/2015 |
| Date of final enrolment | 01/06/2018 |
Locations
Countries of recruitment
- Belgium
Study participating centres
Elsene
1050
Belgium
Jette
1090
Belgium
Sponsor information
University/education
Pleinlaan 2
Elsene
1050
Belgium
"ROR" |
https://ror.org/006e5kg04 |
|---|
Funders
Funder type
University/education
No information available
Results and Publications
| Intention to publish date | 01/01/2016 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Other |
| Publication and dissemination plan | Publication 1: Response of dendritic cells to Nanobodies: planned beginning 2016 Publication 2: Response of T cells to Nanobodies: planned end 2016 Publication 3: Optimised sequence of Nanobodies with reduced immunogenicity: planned half 2018 |
| IPD sharing plan | Not provided at time of registration |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 09/03/2021 | 18/11/2021 | Yes | No |
Editorial Notes
18/11/2021: Publication reference added.
